No evidence of large genetic effects on steroid response in asthma patients

Journal of Allergy and Clinical Immunology

Volumn 139, Issue 3, 2017, Pages 797-803.e7

  Mosteller, Michael ^a   Hosking, Louise ^a   Murphy, Kay ^a   Shen, Judong ^b   Song, Kijoung ^b   Nelson, Matthew ^b   Ghosh, Soumitra ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

asthma; fluticasone; genome wide association studies; inhaled corticosteroids; pharmacogenetics; Steroid response

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; PLACEBO; SHORT ACTING DRUG; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID;

ADULT; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PARALLEL DESIGN; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; CLINICAL TRIAL; CONTROLLED STUDY; GENETIC VARIATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84981709063     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.05.032     Document Type: Article

References (37)

1. Masoli, M., Fabian, D., Holt, S., Beasley, R., The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004), 469–478.
2. Yang, J., Benyamin, B., McEvoy, B.P., Gordon, S., Henders, A.K., Nyholt, D.R., et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 42 (2010), 565–569.
3. Weiss, S.T., New approaches to personalized medicine for asthma: where are we?. J Allergy Clin Immunol 129 (2012), 327–334.
4. Hawkins, G.A., Lazarus, R., Smith, R.S., Tantisira, K.G., Meyers, D.A., Peters, S.P., et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol 123 (2009), 1376–1383.
5. Lopert, A., Rijavec, M., Zavbi, M., Korosec, P., Flezar, M., Asthma treatment outcome in adults is associated with rs9910408 in TBX21 gene. Sci Rep, 3, 2013, 2915.
6. Tantisira, K.G., Hwang, E.S., Raby, B.A., Silverman, E.S., Lake, S.L., Richter, B.G., et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A 101 (2004), 18099–18104.
7. Cho, S.H., Park, B.L., Shin, S.W., Heo, J.S., Park, J.S., Park, S.W., et al. Association between WDR21A polymorphisms and airway responsiveness to inhaled corticosteroids in asthmatic patients. Pharmacogenet Genomics 22 (2012), 327–335.
8. Tantisira, K.G., Lasky-Su, J., Harada, M., Murphy, A., Litonjua, A.A., Himes, B.E., et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med 365 (2011), 1173–1183.
9. Park, H.W., Dahlin, A., Tse, S., Duan, Q.L., Schuemann, B., Martinez, F.D., et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol 133 (2014), 664–669.
10. Tantisira, K.G., Damask, A., Szefler, S.J., Schuemann, B., Markezich, A., Su, J., et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med 185 (2012), 1286–1291.
11. Tantisira, K.G., Lake, S., Silverman, E.S., Palmer, L.J., Lazarus, R., Silverman, E.K., et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 13 (2004), 1353–1359.
12. Tantisira, K.G., Lazarus, R., Litonjua, A.A., Klanderman, B., Weiss, S.T., Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics 18 (2008), 733–737.
13. Hosking, L., Bleecker, E., Ghosh, S., Yeo, A., Jacques, L., Mosteller, M., et al. GLCCI1 rs37973 does not influence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol 133 (2014), 587–589.
14. Vijverberg, S.J., Tavendale, R., Leusink, M., Koenderman, L., Raaijmakers, J.A., Postma, D.S., et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics 15 (2014), 799–806.
15. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J., Abecasis, G.R., Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 44 (2012), 955–959.
16. Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Handsaker, R.E., et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491 (2012), 56–65.
17. Wigginton, J.E., Cutler, D.J., Abecasis, G.R., A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76 (2005), 887–893.
18. Aulchenko, Y.S., Struchalin, M.V., van Duijn, C.M., ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinform, 11, 2010, 134.
19. Kutalik, Z., Johnson, T., Bochud, M., Mooser, V., Vollenweider, P., Waeber, G., et al. Methods for testing association between uncertain genotypes and quantitative traits. Biostatistics 12 (2011), 1–17.
20. Li, J., Ji, L., Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb) 95 (2005), 221–227.
21. Li, M.X., Yeung, J.M., Cherny, S.S., Sham, P.C., Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. Hum Genet 131 (2012), 747–756.
22. Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M., Chen, W.M., Robust relationship inference in genome-wide association studies. Bioinformatics 26 (2010), 2867–2873.
23. Willer, C.J., Li, Y., Abecasis, G.R., METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26 (2010), 2190–2191.
24. Lee, S., Wu, M.C., Lin, X., Optimal tests for rare variant effects in sequencing association studies. Biostatistics 13 (2012), 762–775.
25. Yang, J., Lee, S.H., Goddard, M.E., Visscher, P.M., GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 88 (2011), 76–82.
26. Goodman, S.N., A comment on replication, p-values and evidence. Stat Med 11 (1992), 875–879.
27. Halsey, L.G., Curran-Everett, D., Vowler, S.L., Drummond, G.B., The fickle P value generates irreproducible results. Nat Methods 12 (2015), 179–185.
28. Mougey, E.B., Chen, C., Tantisira, K.G., Blake, K.V., Peters, S.P., Wise, R.A., et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J 13 (2013), 242–250.
29. Moffatt, M.F., Gut, I.G., Demenais, F., Strachan, D.P., Bouzigon, E., Heath, S., et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 363 (2010), 1211–1221.
30. Rossios, C., To, Y., To, M., Ito, M., Barnes, P.J., Adcock, I.M., et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 670 (2011), 244–251.
31. Reddy, T.E., Gertz, J., Crawford, G.E., Garabedian, M.J., Myers, R.M., The hypersensitive glucocorticoid response specifically regulates period 1 and expression of circadian genes. Mol Cell Biol 32 (2012), 3756–3767.
32. John, S., Sabo, P.J., Thurman, R.E., Sung, M.H., Biddie, S.C., Johnson, T.A., et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet 43 (2011), 264–268.
33. Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
34. Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R., et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 365 (2011), 1088–1098.
35. Bhakta, N.R., Solberg, O.D., Nguyen, C.P., Nguyen, C.N., Arron, J.R., Fahy, J.V., et al. A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy, 3, 2013, 24.
36. Moore, W.C., Meyers, D.A., Wenzel, S.E., Teague, W.G., Li, H., Li, X., et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181 (2010), 315–323.
37. Moore, W.C., Fitzpatrick, A.M., Li, X., Hastie, A.T., Li, H., Meyers, D.A., et al. Clinical heterogeneity in the severe asthma research program. Ann Am Thorac Soc 10 (2013), S118–S124.